fda glp-1 warning letters october 2025 CDER Jump 50% in FY — What That Means for Industry FDA unleashes warning letters to
Description
Phentermine is especially beneficial for patients with glp-1 therapy or those who struggle with weight management alongside metabolic challenges

"Semaglutide will definitely harm your baby" Reality: There's currently no evidence of harm to breastfed infants from maternal semaglutide use
This creates a win-win opportunity: Employees get the support they need, and employers can offer a valuable solution without adding pressure to their pharmacy budgets

For now, many patients and providers remain on unsteady ground

Eli Lilly hasn't announced a brand name for retatrutide yet
References [1] S
